Colospan offers a unique alternative to the diverting stoma by providing a temporary intraluminal bypass which helps reduce the contact of fecal materials with the anastomotic site. This temporary diversion solution is removed without surgery in under two weeks and aims to minimize post-operative complications for a comfortable recovery.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Investors 1
| Date | Name | Website |
| - | Triventure... | triventure... |
Mentions in press and media 3
| Date | Title | Description |
| 09.10.2024 | Asklepios Altona Clinic, First Hospital in Germany to use Novel CG-100 Intraluminal Device in Rectal Cancer Patients | KFAR SABA, ISRAEL, October 9, 2024 /EINPresswire.com/ -- Colospan Ltd. announced today that Hamburg based Asklepios Altona Clinic is the first Hospital in Germany to use the CG-100 intraluminal bypass device bypass device which is designed ... |
| 13.08.2024 | Colospan Receives FDA Breakthrough Device Designation for Its Intraluminal Bypass Device | CAMBRIDGE, MA, UNITED STATES, August 13, 2024 /EINPresswire.com/ -- Colospan, which develops novel solutions for colorectal surgery, announced today that the United States Food and Drug Administration (FDA) has granted Breakthrough Device D... |
| 29.05.2024 | Colospan Announces Extended IDE Approval for Its Intraluminal Bypass Device – an Alternative Approach to Diverting Stoma | CAMBRIDGE, MA, UNITED STATES, May 29, 2024 /EINPresswire.com/ -- Colospan, which develops novel solutions for colorectal surgery, announced today that the United States Food and Drug Administration (FDA) has approved a product line extensio... |